News
Company News: Curetis Announces Financial Results for the First Nine Months of 2018
– Total year-on-year revenue growth of 43% globally, 207% in EMEA direct selling markets
– Initial traction in U.S. market after Unyvero launch
– Strategic collaboration with BCB in Greater China expanded
– Commercial reach expanded to Northern Africa, South America and Asia
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today reported its financial results for the first nine months ended September 30, 2018, and provided a business update for the third quarter of 2018. Read more…
Company News: Curetis Accelerates 510(k) Submission Preparation for Unyvero LRT in BAL Specimen Based on Positive FDA Feedback
— S. FDA and Curetis agree on 510(k) requirements for clearing BAL as additional sample type for Unyvero LRT
— S. commercial roll-out gaining traction, with first dozen Unyvero Analyzers placed and first commercial evaluation agreements signed
Curetis N.V. (the “Company” and, together with its subsidiaries, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that following a recent meeting, the U.S. FDA has confirmed the suitability of the 510(k) clearance pathway for Curetis’ Unyvero LRT Application Cartridge specifically optimized for the detection of microbial pathogens in bronchoalveolar lavage (“BAL”) samples. Read more…
Company News: monikit receives EUR 1.86 million funding for the further development of its mobile seizure-detector for epileptics
— Supported by Life Science Inkubator (LSI) Bonn
— Novel system for the detection and documentation of epileptic seizures allows for personalized treatment
Tuebingen-based spin-out project monikit today announced the start of its incubation at Life Science Inkubator (LSI) Bonn. The incubation comes with a project funding of EUR 1.86 million and is supported by seasoned life science and medtech experts.
Company News: ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
ISA Pharmaceuticals B.V., a clinical-stage immuno-oncology company, today announced that its Chief Scientific Officer Prof. Cornelis Melief has been selected by the European Society for Medical Oncology (ESMO) to receive the 2018 ESMO Immuno-Oncology Award in recognition of his life’s work in studying the interactions of the immune system with cancer. Read more…